Lipase Levels and Coronavirus Disease 2019

Completed

• Conditions: Pancreatitis; Lipase Increased

• Registration Number: NCT05601258
• Lead Sponsor: Uşak University

Brief Summary

Although COVID-19 disease due to Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) affects the respiratory tract, heart and coagulation system, symptoms of gastrointestinal system involvement such as abdominal pain, nausea, vomiting and diarrhea are also common.

In this study, it was aimed retrospective analysis of clinical and laboratory data of patients who developed pancreatic injury and acute pancreatitis in the course of COVID 19 disease.

Detailed Description

Not available

Study Timeline

• Study Start: 2020-03-31
• Primary Completion: 2021-07-09
• Study Completion: 2021-07-09
• Status Verified: 2022-10
• Study First Submitted: 2022-10-26
• Study First Submitted QC: 2022-10-26
• Last Update Submitted: 2022-10-26
• Study First Posted: 2022-11-01
• Last Update Posted: 2022-11-01

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Not specified
• Target Recruitment: 4000

Inclusion Criteria

• Patients with lipase levels measured during COVID-19

Exclusion Criteria

Patients with age <18 years Patients with pregnancy Patients whose lipase levels were not measured in the course of COVID-19 Patients with known solid organ malignacy Patients with known hematologic malignacy

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The frequency of lipase enzyme elevation will be compared	From 31th March 2020 until 9th July 2021
The mortaliy rate will be compared	From 31th March 2020 until 9th July 2021

Trial Locations

Locations (1)

Cevdet Duran; 🇹🇷 Usak, Turkey